LEXX News and Press, Lexaria Bioscience Corp. From 02/15/24

2024-02-15 08:25:02 ET More on Lexaria Bioscience Corp. Lexaria submits IND to begin Phase 1b study of DehydraTECH-CBD Lexaria stock rallies 20% on positive GLP-1 drug delivery study Read the full article on Seeking Alpha For further details see: Lexaria ...

KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common ...

Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, announced the final results from its completed human Pilot Study #1 that sought to evaluate the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of the glucagon-like peptide-1 (&#...

Lexaria, a global innovator in drug delivery platforms, just announced ambitious plans for the 2024 calendar year The letter confirms that the 2024 plans have been made possible by significant strides that were made by the company in 2023 Lexaria looks to build on the momentum gained from the...

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the im...

2024-01-30 10:46:15 ET More on Lexaria Bioscience Corp. Lexaria stock rallies 20% on positive GLP-1 drug delivery study Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical earnings data for Lexaria Bioscience Corp. Financial information...

KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, it submitted its much-anticipated Investigational New Drug ("IND") application with the U.S. F...

(TheNewswire) Kelowna, British Columbia – TheNewswire -- January 30, 2024 – Lexaria Bioscience Corp. (Nasdaq:LEXX ) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that, on J...

Lexaria, a global innovator in drug delivery platforms, has announced its GLP-1 research plans for the 2024 calendar year The company will kick off its chronic dosing animal study in March/April, followed by the human pilot study #2, kicking off at around the same time The third human pilot s...